Antiviral treatment for preventing postherpetic neuralgia

Li, Qifu; Zhang, Quanwei; Zhou, Muke; Zhou, Dong

doi:10.1002/14651858.cd006866

Cited by 23 publications

(24 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A recent Cochrane review of five trials comparing acyclovir to placebo and one trial comparing famciclovir to placebo found little difference in prevalence of PHN 6 months after rash onset; however, the meta-analysis was limited to two of the acyclovir trials with the required data (summary RR 1.05; 95% CI, 0.87-1.27) [83]. This finding partly contrasted previous reviews in which different definitions of PHN were used.…”

Section: Antiviralsmentioning

confidence: 71%

“…A randomized controlled trial of 419 adults showed a significant reduction in median duration of PHN (although no reduction in PHN incidence) when famciclovir was given using a standard regime [85]. The authors of the Cochrane review suggested further trials be conducted on famciclovir and valacyclovir to clarify their role in reducing duration and severity of PHN [83]. These newer agents are, however, significantly more expensive compared to acyclovir and are currently infrequently prescribed.…”

Section: Antiviralsmentioning

confidence: 99%

See 1 more Smart Citation

The Epidemiology and Prevention of Herpes Zoster

2012

View full text Add to dashboard Cite

Herpes zoster is a common disease among older individuals, affecting approximately 25% of people in their lifetime and resulting in appreciable morbidity. The risk of zoster increases sharply with age and immunosuppression, yet relatively little is known about other risk factors for zoster. A vaccine for zoster is now available that holds the potential to reduce incidence of zoster and its complications. In this review, the recent literature on zoster incidence and potential risk factors for the disease are summarized. Current methods of preventing zoster and its associated morbidity are discussed, including zoster vaccine and the use of antivirals.

show abstract

Section: Antiviralsmentioning

confidence: 71%

Section: Antiviralsmentioning

confidence: 99%

The Epidemiology and Prevention of Herpes Zoster

2012

View full text Add to dashboard Cite

show abstract

“…36,37 Although 90% of the study cohort was initially given antiviral treatment, herpes zoster and post herpetic neuralgia severely affected all health domains and activities of daily living. In addition, a recent Cochrane meta-analysis did not provide evidence to support the use of antivirals to prevent postherpetic neuralgia, 38 although evidence is lacking for some specific antivirals.…”

Section: Limitationsmentioning

confidence: 99%

The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study

Drolet¹,

Brisson²,

Schmader³

et al. 2010

Canadian Medical Association Journal

251

196

View full text Add to dashboard Cite

H erpes zoster, which is characterized by dermatomal pain and vesicular rash, 1,2 results from reactivation of the varicella-zoster virus. 3,4 The average lifetime risk of herpes zoster in developed countries is estimated to be about 30% [5][6][7] and increases with increasing life expectancy. The most common complication of herpes zoster, and one of the most challenging to treat, is post herpetic neuralgia, a painful condition often defined as pain persisting for more than 90 days after rash onset.8 According to this definition, postherpetic neuralgia is estimated to occur in 8%-27% of people with herpes zoster overall.9-14 The risk of postherpetic neuralgia increases markedly with age. 15The Shingles Prevention Study, a randomized doubleblind placebo-controlled trial, showed that a live-attenuated varicella-zoster virus vaccine was safe and effective in preventing herpes zoster and postherpetic neuralgia among people 60 years of age and older.13 Given these promising results, policy-makers and clinicians are being asked to make recommendations regarding the use and funding of the herpes zoster vaccine. To do this, evidence on the burden of herpes zoster from the patient's perspective is required. The only data available on the impact of herpes zoster on health-related quality of life comes from two short-term studies.16,17 Clinical reports and cross-sectional surveys [18][19][20] have also suggested that post herpetic neuralgia can profoundly impair quality of life. However, no study followed a cohort of patients with newly diagnosed herpes zoster for a sufficient period to assess postherpetic neuralgia and describe the associated impact on quality of life.We undertook a multicentre prospective study to describe the impact of herpes zoster and postherpetic neuralgia on health-related quality of life.

show abstract

“…Antiviral therapy after the onset of shingles has not shown efficacy for the prevention of PHN. 21 The herpes zoster (shingles) vaccine (ZOS; Zostavax, Merck), was approved by the FDA in May 2006 for use in persons Ն60 years of age. Although the FDA licensed ZOS for use in adults aged 50 to 59 years in March 2011, the Advisory Committee on Immunization Practices (ACIP) so far has declined to extend a formal recommendation for this age range because of concerns about limitations in the vaccine supply and uncertainty about the duration of the vaccine's protection in younger adults.…”

Section: Herpes Zoster Vaccinementioning

confidence: 99%

Update on Adult Immunizations

Wolfe

2012

The Journal of the American Board of Family Medicine

View full text Add to dashboard Cite

Antiviral treatment for preventing postherpetic neuralgia

Cited by 23 publications

References 20 publications

The Epidemiology and Prevention of Herpes Zoster

The Epidemiology and Prevention of Herpes Zoster

The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study

Update on Adult Immunizations

Contact Info

Product

Resources

About